Engineering Optimized Biotherapeutics



Course Description:
Engineering is an essential component in the generation of optimized biotherapeutics. This course will give an overview of the optimization of scFvs to improve stability and activity, as well as, assembly of these candidates into a final therapeutic antibody-like molecule. Fc engineering for PK extension and effector function will also be explored. Participants will gain a general understanding of engineering and selection techniques used for the optimization of biotherapeutics.


2:00-3:45 Introductory Lecture and Discussion


  • Optimization of scFvs
  • Assembly of scFv candidates into an optimized final therapeutic molecule
  • Fc engineering

3:45-4:00 Refreshment Break

4:00-4:30 Group Exercise: Engineering Jeopardy

4:30-5:00 Closing Take Home Message


Brenda StevensTrainer: Brenda Stevens, Senior Scientist, Protein Engineering, ZymoGenetics, A Bristol-Myers Squibb Company

Brenda Stevens is a senior scientist at ZymoGenetics, A Bristol-Myers Squibb Company. She has a strong background in protein/antibody engineering and antibody humanization. She began her career at Fred Hutchinson Cancer Research Center in an Antibody Engineering lab headed by Jefferson Foote. She is currently responsible for leading protein engineering efforts for therapeutic candidate optimization, including; lead candidate molecule design, reagent generation, and oversight of candidate molecule characterization.



By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs